Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Denmark, oncology-based Pharmacosmos today announced that it has assumed the worldwide rights, excluding select Asia-Pacific ...

The U.S. Federal Drug Administration (FDA) has granted Incyclix Bio Fast Track designation for INX-315 to treat ...

In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers.

Ampaire Inc., a leader in hybrid electric aircraft technology, announced today that the Federal Aviation Administration (FAA) ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 ...

Phase 3 results Emactuzumab (SynOx Therapeutics) Immunoglobulin G1 monoclonal antibody that targets the CSF-1 receptor Treatment of tenosynovial giant cell tumors in patients who are not amenable ...